Verition Fund Management
BNTX icon

Verition Fund Management’s BioNTech BNTX Stock Holding History

Verition Fund Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,600
Closed -$438K – 2397
2025
Q4 		$438K Sell
4,600
-14,800
-76% -$1.49M ﹤0.01% 2766
2025
Q3 		$1.91M Buy
19,400
+11,400
+143% +$1.22M 0.01% 2021
2025
Q2 		$852K Buy
+8,000
New +$808K ﹤0.01% 2585

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Verition Fund Management's BNTX Position: Q2 2026 in Review

Verition Fund Management reduced its BioNTech (BNTX) stake by 9.1% in Q2 2026, selling an estimated $44K and leaving 4,658 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Verition Fund Management first reported a position in BNTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.93M in Q4 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Verition Fund Management held 4,658 shares of BioNTech worth $433K as of Q2 2026.
  • Verition Fund Management sold 468 BioNTech shares in Q2 2026, an estimated $44K.
  • BioNTech made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1675 holding.
  • Verition Fund Management first reported a position in BioNTech in Q4 2020 and has held it in 7 quarters since.
  • Verition Fund Management's BioNTech position peaked at $1.93M in Q4 2024.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.